Replies to post #169168 on Biotech Values

[oc631]

GILD’s VALENCE study was mentioned at the recent advisory panel, but the data were apparently not yet complete. We can now set aside the mathematical modeling performed by the FDA to extrapolate the SVR rate for >12w treatment in GT3.

Right. The data was close at hand. Apologies go out the FDA likewise.

[oc631]

Did you notice the LONESTAR-2 GT3 Sofo/PegRiba data was missing from the PR?